Har-Noy, M., Lausoontornsiri, W. (2025). A phase 2, multicenter, open-label study of AlloStim combined with anti-PD-L1immunotherapy as 4L therapy in patients with MSS/pMMR metastatic colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.tps318